A 4-Year Follow-Up of Levodopa-Entacapone-Carbidopa Intestinal Gel Treatment in Parkinson's Disease.

IF 2.6 4区医学 Q2 CLINICAL NEUROLOGY

Movement Disorders Clinical Practice Pub Date : 2024-10-24 DOI:10.1002/mdc3.14240

Mezin Öthman, Dag Nyholm

{"title":"A 4-Year Follow-Up of Levodopa-Entacapone-Carbidopa Intestinal Gel Treatment in Parkinson's Disease.","authors":"Mezin Öthman, Dag Nyholm","doi":"10.1002/mdc3.14240","DOIUrl":null,"url":null,"abstract":"Background: Levodopa-entacapone-carbidopa intestinal gel (LECIG) infusion was introduced to the Swedish market in 2019 for Parkinson's disease (PD) with motor fluctuations. Long-term data are lacking.Objectives: To study long-term data on LECIG treatment.Methods: A retrospective analysis of the first 24 patients receiving LECIG in Sweden from 2019 to 2023.Results: Five of 24 (21%) patients discontinued LECIG because of side effects, mostly diarrhea. Eight of the 24 (33%) patients died while receiving LECIG. Eleven of 24 (46%) patients were still on LECIG. Median (range) for disease and treatment duration was 19 (9-30) and 3.6 (3.1-4.0) years, respectively, whereas health-related quality of life scales showed median (interquartile range; n) Parkinson's Disease Questionnaire 8-item summary index scores of 38 (4; n = 7), EuroQol 5D scores of 0.59 (0.17; n = 7), and EQ-5D visual analogue scale scores of 65 (10; n = 7).Conclusions: LECIG infusion is a viable treatment option for PD patients with motor fluctuations, for up to 4 years in our cohort.","PeriodicalId":19029,"journal":{"name":"Movement Disorders Clinical Practice","volume":" ","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Movement Disorders Clinical Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/mdc3.14240","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Levodopa-entacapone-carbidopa intestinal gel (LECIG) infusion was introduced to the Swedish market in 2019 for Parkinson's disease (PD) with motor fluctuations. Long-term data are lacking.

Objectives: To study long-term data on LECIG treatment.

Methods: A retrospective analysis of the first 24 patients receiving LECIG in Sweden from 2019 to 2023.

Results: Five of 24 (21%) patients discontinued LECIG because of side effects, mostly diarrhea. Eight of the 24 (33%) patients died while receiving LECIG. Eleven of 24 (46%) patients were still on LECIG. Median (range) for disease and treatment duration was 19 (9-30) and 3.6 (3.1-4.0) years, respectively, whereas health-related quality of life scales showed median (interquartile range; n) Parkinson's Disease Questionnaire 8-item summary index scores of 38 (4; n = 7), EuroQol 5D scores of 0.59 (0.17; n = 7), and EQ-5D visual analogue scale scores of 65 (10; n = 7).

Conclusions: LECIG infusion is a viable treatment option for PD patients with motor fluctuations, for up to 4 years in our cohort.

查看原文本刊更多论文

左旋多巴-恩他卡朋-卡比多巴肠道凝胶治疗帕金森病的 4 年随访。

背景：左旋多巴-恩他卡朋-卡比多巴肠道凝胶（LECIG）输液于2019年进入瑞典市场，用于治疗伴有运动波动的帕金森病（PD）。目前尚缺乏长期数据：研究 LECIG 治疗的长期数据：方法：对2019年至2023年在瑞典接受LECIG治疗的首批24名患者进行回顾性分析：24名患者中有5名（21%）因副作用（主要是腹泻）而中断LECIG治疗。24名患者中有8名（33%）在接受LECIG治疗期间死亡。24 名患者中有 11 名（46%）仍在接受 LECIG 治疗。疾病和治疗持续时间的中位数（范围）分别为19（9-30）年和3.6（3.1-4.0）年，而健康相关生活质量量表显示帕金森病问卷8项汇总指数的中位数（四分位距；n）为38（4；n=7），EuroQol 5D评分为0.59（0.17；n=7），EQ-5D视觉模拟量表评分为65（10；n=7）：结论：输注 LECIG 是治疗运动波动型帕金森病患者的一种可行方法，在我们的队列中可持续长达 4 年。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Movement Disorders Clinical Practice CLINICAL NEUROLOGY-

CiteScore

4.00

自引率

7.50%

发文量

218

期刊介绍： Movement Disorders Clinical Practice- is an online-only journal committed to publishing high quality peer reviewed articles related to clinical aspects of movement disorders which broadly include phenomenology (interesting case/case series/rarities), investigative (for e.g- genetics, imaging), translational (phenotype-genotype or other) and treatment aspects (clinical guidelines, diagnostic and treatment algorithms)